IMAB | tickerfilter.com

Fundamental analysis

35%

Profitability 25%

Dept financing 16%

Liquidity 50%

Performance 45%

Company vs Stock growth

N/A

+ Add row to compare

Performance

5 Days

0.88%

1 Month

-15.52%

3 Months

-34.67%

6 Months

-47.63%

1 Year

-61.89%

2 Year

-80.78%

Key data

Stock price

$0.69

P/E Ratio

0.00

DAY RANGE

$0.64 - $0.78

EPS

N/A

52 WEEK RANGE

$0.60 - $2.00

52 WEEK CHANGE

-$62.31

MARKET CAP

91.398 M

YIELD

N/A

SHARES OUTSTANDING

80.883 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

1.57

PUBLIC FLOAT

AVERAGE 10 VOLUME

$364,457

AVERAGE 30 VOLUME

$244,156

Company detail

CEO: Xiu X. Zhu
Region: US
Website: i-mabbiopharma.com
Employees: 380
IPO year: 2020

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

I-Mab discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases. Its product candidates also includes Enoblituzumab, which has completed Phase 2 clinical trials for head and neck cancer, and other oncology diseases.

IMAB - I-Mab